IPIna Palii

Ina Palii

*This is an algorithmically generated author record based on publicly available information.

Ina Palii has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pulmonary Hypertension in Children - New Insights of Diagnosis and Management

    by Ina Palii, Iulia Rodoman, Daniela Palega, Lucia Pirtu, Svetlana Sciuca

    Sciendo provides publishing services and solutions to academic and professional organizations and individual authors. We publish journals, books, conference proceedings and a variety of other publications.

  • First manifestation and evolution of early left ventricular dysfunction in children with Duchenne muscular dystrophy

    by Iulia Rodoman, Alexandr Dorif, Ina Palii, Victoria Sacara

    Background: Standard pediatric cardiology examinations and echocardiography fail to discover when the cardiomyopathy will occur in patient with Duchenne muscular dystrophy (DMD). Noninvasive markers are needed to fill this gap. Material and methods: This cohort study included a total number of 30 children (21 children (70%) with DMD and 9 (30%) healthy children. Blood samples were used for biochemical (level of creatine kinase, creatine kinase-MB, lactate dehydrogenase) and miRNA (presence of miR133a 3p, miR133b 3p, miR206 3p, miR208a 3p, miR208b 3p) analysis. All patients underwent partial conventional echocardiography ECOCG and Speckle Tracking. Results: The children in the working group presented compared to healthy children: FCC values increased by 15 (71%) vs 2 (22%), high levels of CK, CK-MB, LDH, which is characteristic for the disease and reflects its stage. Also, there is a decrease in systolic function indicators in the working group: mean FE 59 ± 3.8 %, and GLS: -16.2 ± 3.1%. MiRNA analyses confirmed the presence of miR133a 3p, miR133b 3p, miR206 3p, miR208a 3p, miR208b 3p in both working and control group. Conclusions: For the first time in the Republic of Moldova, we developed and adapted protocols for RNA extraction from human blood, performing screening of specific miRNA in the serum of patients with DMD and healthy children. Also, altered LV strain notwithstanding a normal or mildly modified LVEF represents an essential viewpoint for prospective pediatric drug trials in DMD-related cardiomyopathy prevention.

  • Open Access

    Correlation between echocardiographic parameters of left ventricle and glycosylated hemoglobin in children with type 1 Diabetes Mellitus

    by Valeriu Esanu, Ina Palii

    Introduction. Deterioration of left ventricular (LV) parameters in Diabetes Mellitus (DM) can occur in the absence of other heart problems. An association between glycosylated hemoglobin (HbA1c) and changes of the LV parameters in DM has been reported. However, data regarding this association model in children with Type 1 Diabetes Mellitus (T1DM) are limited. The purpose of the work was to investigate the association between HbA1c and the LV parameters in pediatric patients. Material and methods. The study was conducted on 28 children with T1DM ((aged 10 - 18 years, gender M (15)/F (13), duration ≥5 years). The clinical (standard medical examination) and paraclinical (biochemical dosage – HbA1c, echocardiography – LV functional and structural parameters) data was carried out. Statistical analysis used the SPSS version 20. Results. The correlational study between the HbA1c and the LV parameters revealed a statistically significant positive correlation coefficient with aortic root diameter (mm) (r=0.7**, p<0.001), left atrium (mm) (r=0.8**, p<0.001 LV diastolic diameter (mm) (r=0.7**, p<0.001), LV systolic diameter (mm) (r=0.7**, p<0.001), septal wall thickness (mm) (r=0.5*, p=0.036), posterior wall thickness (mm) (r=0.5*, p=0.032), LV diastolic volume (ml) (r=0.5*, p=0.025), LV systolic volume (ml) (r=0.6**, p=0.01), ejection fraction (%) (r=0.7**, p=0.001), fractional shortening (%) (r=0.6**, p=0.002). Conclusions. The results of the study show that in children with T1DM, the increase value of the HbA1c is associated with a consensual and proportional increase in the values of the parameters of the left ventricle. Введение. Нарушение параметров левого желудочка (ЛЖ) при диабете (СД) может иметь место при отсутствии других проблем с сердцем. Сообщалось о связи между значениями гликозилированного гемоглобина (HbA1c) и изменениями параметров ЛЖ при СД. Однако данные об этой модели ассоциации у детей с диабетом 1 типа (СД1) ограничены. Цель статьи. Изучение связи между параметрами HbA1c и нарушениями параметров ЛЖ у детей. Материалы и методы. В исследование были включены 28 детей с СД1 (возраст 10–18 лет, пол M (15) / Ж (13), продолжительность ≥5 лет). Была проведена клиническая оценка (стандартное медицинское обследование) и параклиническая оценка (биохимическое дозирование - HbA1c, эхокардиография - функциональные и структурные параметры ЛЖ). Статистический анализ - версия 20 SPSS. Результаты. Исследование корреляции между параметрами HbA1c и ЛЖ выявило статистически значимый положительный коэффициент корреляции с диаметром аорты (мм) (r = 0,7 **, p <0,001), левое предсердие (мм) (r = 0,8 **, p <0,001) диастолический диаметр ЛЖ (мм) (r = 0,7 **, p <0,001), систолический диаметр ЛЖ (мм) (r = 0,7 **, p <0,001), межжелудочковая перегородка (мм)) (r = 0,5 *, p = 0,036 ), задняя стенка ЛЖ (мм) (r = 0,5 *, p = 0,032), диастолический объем ЛЖ (мл) (r = 0,5 *, p = 0,025), систолический объем ЛЖ (мл) (r = 0,6 ** , p = 0,01), фракция выброса (%) (r = 0,7 **, p = 0,001), фракция шортенинга (%) (r = 0,6 **, p = 0,002). Выводы. Результаты исследования показали, что у детей с сахарным диабетом 1 типа повышение HbA1c связано с согласованным увеличением пропорционально значениям параметров левого желудочка.

  • Cardiomyopathy secondary to Duchenne muscular dystrophy in children

    by Iulia Rodoman, Ina Palii, Victoria Sacara, Sergiu Gladun

    Background: Cardiomyopathy (CM) associated with Duchenne muscular dystrophy (DMD) is a commonly recognized appearance of this neuromuscular disease, significantly increased morbidity and mortality, as well as the necessity for cardiological management. CM in DMD is defined by left ventricular (LV) systolic dysfunction and both atrial and ventricular dysrhythmias and is associated with higher mortality than other cases of pediatric dilated CMs. Notwithstanding the high rate of cardiac involvement, patients are usually asymptomatic despite significant LV dysfunction, because of likely poor mobility that masks the usual heart failure (HF) symptoms. Also, imagistic predictors are provided to be very helpful in defining early LV dysfunction, especially electrocardiogram and cardiac imaging (transthoracic echocardiography, speckle-tracking, cardiac magnetic resonance) are used to detect the onset and progression of dilated cardiomyopathy (DCM) in DMD. Conclusions: As most DMD patients are asymptomatic for a long time of their life, so identifying predictors of HF is crucial to support these patients. Ventricular dysfunction based on the ejection fraction (EF) measurement helps to choose therapy. In the case of early DCM (LVEF≥50%) the great purpose is to prevent ventricular dysfunction incipience with first-line HF therapy with Angiotensin-converting-enzyme inhibitors (ACE-I) or angiotensin receptor blockers (ARBs). Current guidelines recommend the use of conventional HF medication in case of disease progression and DCM with MidRange Reduction of LV EF (40-49%). The therapeutic approach for patients with DCM and severe ventricular dysfunction (<40%) has been studied less profoundly and contemporary guidelines recommend all drugs used for HF treatment